Our previous studies revealed that a proportion of advanced NSCLC patients who experience disease progression during EGFR‐TKI therapy could benefit from previously administered targeted agents after cisplatin‐pemetrexed chemotherapy.28 Here, EGFR is linked to non-small cell lung carcinoma.